- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04462952
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Monotherapy and in Combination With Chemotherapy in Japanese Patients With Advanced Solid Tumours
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Primary objective:
Part A:
To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for adavosertib
Secondary objective:
To determine the PK profile of adavosertib To describe adavosertib's preliminary anti-tumour activity using the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Part B:
To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for adavosertib in combination with gemcitabine
Secondary objective:
To determine the PK profile of adavosertib plus gemcitabine To describe preliminary anti-tumour activity of adavosertib in combination with gemcitabine using the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 To assess the drug interaction between adavosertib and gemcitabine
Overall design:
This is a phase I, open-label study to assess the safety, tolerability, PK and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 parts, monotherapy (part A) and chemotherapy combination (part B). At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort. The total number of subjects will depend upon the available data in each cohort and the Safety Review Committee (SRC)'s decision.
Number of Subjects:
At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort.
Treatments and treatment duration:
Subjects in each part will receive the study treatments as described below:
Part A: Adavosertib by mouth (PO) once daily (QD) for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle.
Part B: Adavosertib PO will be taken QD on Days 2, 3, 9, 10, 16, and 17. Gemcitabine will be administered by intravenous infusion according to institutional standards on Days 1, 8, and 15 of each 28-day cycle.
Subjects will be allowed to continue adavosertib until disease progression, intolerable toxicity, or discontinuation criteria have been met.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chuo-ku, Japan, 104-0045
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Major Inclusion Criteria:
- Japanese patients ≥20 years of age at the time of study entry
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0, 1
- Adequate bone marrow reserve or organ function
- Female patients who are not of child-bearing potential, and fertile females of childbearing potential who agree to use adequate contraceptive measures
- Male patients should be willing to use barrier contraception
- Predicted life expectancy ≥12 weeks
- Part A : Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable
- Part B : Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable and additionally, tumours for which gemcitabine is expected to be effective.
- Measurable or non-measurable disease according to RECIST v1.1
Major Exclusion Criteria:
- Use of anti-cancer treatment drug ≤21 days or 5 half-lives (whichever is shorter) prior to Cycle 1 Day 1
- Use of an investigational drug during the past 30 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1
- Common Terminology Criteria for Adverse Events (CTCAE) Grade >1 toxicity from prior therapy
- Inability to swallow oral medication or any other condition that may impact adavosertib intake/absorption
- Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases
- Any of the cardiac diseases currently or within the last 6 months
- Any underlying medical condition that would impair the patient's ability to receive study treatment
- Other invasive malignancy within 5 years prior to Cycle 1 Day 1 except for non-invasive malignancies
- Part B : Presence of apparent radiological findings for interstitial pneumonitis or pulmonary fibrosis with pulmonary symptoms
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adavosertib (AZD1775) monotherapy
Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
|
Adavosertib taken orally
|
Experimental: Adavosertib (AZD1775) in combination with gemcitabine
Dose escalation of adavosertib in combination with gemcitabine for patients with advanced solid tumours
|
Adavosertib taken orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse events
Time Frame: From the informed consent to 30 days post last dose
|
Investigate the safety and tolerability of adavosertib
|
From the informed consent to 30 days post last dose
|
Incidence of Dose-limiting toxicity (DLTs)
Time Frame: From the first dose of Cycle 1 up to the assessment prior to the planned first dose of Cycle 2 (each cycle is 21 days for Part A and 28 days for Part B)
|
Investigate the safety and tolerability of adavosertib
|
From the first dose of Cycle 1 up to the assessment prior to the planned first dose of Cycle 2 (each cycle is 21 days for Part A and 28 days for Part B)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma drug concentration observed (Cmax).
Time Frame: Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
PK parameters will be derived using standard, non-compartmental methods
|
Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
Time of maximum plasma drug concentration observed (tmax).
Time Frame: Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
PK parameters will be derived using standard, non-compartmental methods
|
Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
Area under the plasma concentration-time curve from zero to 24 hours (AUC0-24).
Time Frame: Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
PK parameters will be derived using standard, non-compartmental methods
|
Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
trough plasma concentration (Ctrough).
Time Frame: Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
PK parameters will be derived using standard, non-compartmental methods
|
Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B)
|
Objective response rate (ORR)
Time Frame: Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Defined as the proportion of subjects who have a best overall response of confirmed complete response (CR) or confirmed partial response (PR)
|
Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Disease control rate (DCR)
Time Frame: Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Defined as the proportion of subjects who have a best overall response of confirmed CR,confirmed PR, or stable disease (SD)
|
Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Duration of response (DoR)
Time Frame: Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Defined as the duration from the date of first documentation of response (CR or PR), which is subsequently confirmed, to the date of documented disease progression or death due to any cause in the absence of disease progression
|
Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Progressionfree free survival (PFS)
Time Frame: Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Defined as the time from the first dose of study treatment until the date of objective disease progression or death by any cause (in the absence of progression), regardless of whether the subject withdraws from the study or receives another anti-cancer therapy prior to progression
|
Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.
|
Part B: the drug interaction between adavosertib and gemcitabine.
Time Frame: Part B : Samples will be collected on Cycle 1 Day 2,3 and even Cycle Day 2 for adavosertib and Cycle 1 Day 1 for gemcitabine. (each cycle is 28 days)
|
PK parameters will be derived using standard, non-compartmental methods
|
Part B : Samples will be collected on Cycle 1 Day 2,3 and even Cycle Day 2 for adavosertib and Cycle 1 Day 1 for gemcitabine. (each cycle is 28 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part B: The ctDNA samples will be analysed for predictive biomarkers of response to treatment.
Time Frame: Part B: at screening
|
The samples may be used to develop and validate future in vitro diagnostic tests to identify patients most likely to respond to the treatment.
|
Part B: at screening
|
Part B: The ctDNA samples will be used for additional exploratory research for efficacy, tolerability, or safety assessment.
Time Frame: Part B: Cycle 1 Day 1 (predose), discontinuation, and progression (each cycle is 28 days).
|
These samples will be used for additional exploratory research which may include but is not limited to interrogation of changes in genetic alterations associated with response or resistance to treatment as well as the dynamics of the biomarkers on treatment and potential mechanisms of resistance to treatment.
|
Part B: Cycle 1 Day 1 (predose), discontinuation, and progression (each cycle is 28 days).
|
Part A: Optional exploratory biomarker research in genetic samples from subjects who have consented to participate in the genetic analysis component of the study and exploratory biomarker research for efficacy, tolerability, or safety assessment.
Time Frame: Part A: Cycle 1 Day 1 (each cycle is 21 days).
|
To conduct potential future exploratory research into factors that may influence the progression of cancer and/or response to adavosertib.
|
Part A: Cycle 1 Day 1 (each cycle is 21 days).
|
Part B:Exploratory analyses may be undertaken on the data generated from tumour tissue to identify biomarkers of sensitivity and resistance to treatment and to increase our understanding of the disease (consenting participants only.)
Time Frame: Part B: at screening
|
To conduct potential future exploratory research into factors that may influence the progression of cancer and/or response to adavosertib.
This exploratory analysis may include immunological biomarkers such as PD-L1 expression and tumour infiltrating lymphocytes.
|
Part B: at screening
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D601HC00008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumours
-
AstraZenecaSyneos HealthCompletedAdvanced Solid TumoursUnited States, Spain, Korea, Republic of, United Kingdom
-
EDDC (Experimental Drug Development Centre), A*STAR...ParexelRecruiting
-
RemeGen Co., Ltd.RecruitingAdvanced Solid TumoursChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced Solid Tumours
-
AstraZenecaActive, not recruiting
-
Exscientia AI LimitedBiotrialTerminatedAdvanced Solid TumoursFrance, Belgium
-
RemeGen Co., Ltd.Recruiting
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited States, Spain
Clinical Trials on Adavosertib (AZD1775)
-
AstraZenecaParexelTerminatedAdvanced Solid TumorsUnited Kingdom
-
AstraZenecaCompletedOvarian Cancer | Locally Advanced Solid Tumours | Metastatic Solid TumoursUnited States
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited Kingdom, United States
-
AstraZenecaParexelCompletedUterine Serous CarcinomaUnited States, Italy, Spain, France, Canada
-
Samsung Medical CenterCompletedSmall Cell Lung CancerKorea, Republic of
-
Samsung Medical CenterTerminated
-
NYU Langone HealthTerminatedAcute Myeloid Leukemia | Myelodysplastic Syndromes | MyelofibrosesUnited States
-
Dana-Farber Cancer InstituteAstraZenecaActive, not recruitingUterine CancerUnited States
-
National Cancer Institute (NCI)Completed
-
St. Joseph's Hospital and Medical Center, PhoenixBarbara Ann Karmanos Cancer Institute; American Society of Clinical Oncology; Translational Genomics Research Institute and other collaboratorsCompleted